Blood Cell Ratios as Predictors of Response to Platelet-Rich Plasma in Knee Osteoarthritis
Starting soon
Conditions studied: Knee Osteoarthritis, Osteoarthritis
In brief
Intra-articular platelet-rich plasma (PRP) injection is a widely used treatment for knee osteoarthritis, but patients respond to it very differently and there is currently no simple, inexpensive way to predict who will benefit. The neutrophil-to-lymphocyte ratio (NLR) and related indices derived from a routine complete blood count reflect a person's baseline inflammatory state. This prospective single-arm observational cohort study investigates whether the baseline NLR, together with the platelet-to-lymphocyte ratio (PLR), the systemic immune-inflammation index (SII), and the monocyte-to-lymphocyte ratio (MLR), predicts the clinical response to intra-articular PRP in patients with Kellgren-Lawrence grade 2 to 3 knee osteoarthritis. The investigators will enroll 120 patients aged 40 to 60 years, each of whom receives a standardized course of three leukocyte-poor PRP injections one week apart. Patients are followed for 6 months, and the primary clinical outcome is the change in the WOMAC osteoarthritis index at 6 months. Outcome assessors are blinded to patients' blood-count values. If a baseline blood ratio predicts response, it could become a low-cost tool to guide patient selection for PRP.
Key facts
- Study ID
- NCT07617233
- Run by
- Utku Gürhan
- People needed
- 120
- Starts
- 2026-09-01
- Expected to finish
- 2027-07-01
- Last updated by the study team
- 2026-06-23
Who can join
Age: 40 and older, up to 60. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Age 40 to 60 years
- Symptomatic primary knee osteoarthritis, Kellgren-Lawrence grade 2 or 3 on weight-bearing radiographs
- Body mass index below 40
- Candidate for and scheduled to receive a course of intra-articular platelet-rich plasma for the index knee
- Able and willing to provide written informed consent and to attend the 6-month follow-up schedule
You may not qualify if…
- Systemic inflammatory or autoimmune disease
- Active acute infection at the time of enrollment
- Current anticoagulant or antiplatelet therapy, or current or recent chemotherapy
- Any contraindication to platelet-rich plasma per the 2025 GRIIP recommendations
- Intra-articular injection of the index knee within the previous 6 months
- Inability to comply with the planned follow-up schedule
Where it is running
- University of Kyrenia, Dr. Suat Gunsel Hospital - Department of Orthopaedics and Traumatology — Kyrenia, Cyprus
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.